Renal Function Can Improve at Any Stage of Chronic Kidney Disease
暂无分享,去创建一个
Eric Thervet | P. Houillier | B. Stengel | E. Letavernier | J. Haymann | M. Metzger | F. Vrtovsnik | E. Thervet | M. Froissart | Lise Weis | M. Flamant | C. Gauci | J. Boffa | Lise Weis | Marie Metzger | Jean-Philippe Haymann | Martin Flamant | François Vrtovsnik | Cédric Gauci | Pascal Houillier | Marc Froissart | Emmanuel Letavernier | Bénédicte Stengel | Jean-Jacques Boffa
[1] B. Astor,et al. Kidney function can improve in patients with hypertensive CKD. , 2012, Journal of the American Society of Nephrology : JASN.
[2] F. Dekker,et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[3] A. Fogo,et al. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. , 1991, Kidney international.
[4] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[5] G. Beck,et al. The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .
[6] Bertram L Kasiske,et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. , 2011, Kidney international.
[7] R. Garrick. Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes , 2011 .
[8] Chris Jones,et al. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] H. Toutenburg. Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S. , 1974 .
[10] M. Tonelli,et al. Progression of kidney dysfunction in the community-dwelling elderly. , 2006, Kidney international.
[11] Tom Greene,et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.
[12] Javier Zamora,et al. Similar renal decline in diabetic and non-diabetic patients with comparable levels of albuminuria. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] D. Kohan,et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.
[14] S. Nielsen,et al. Thirty Years with HIV Infection—Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors , 2012, AIDS research and treatment.
[15] J. Boffa,et al. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. , 2003, Journal of the American Society of Nephrology : JASN.
[16] Liang Li,et al. Longitudinal progression trajectory of GFR among patients with CKD. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] T. Akizawa,et al. Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.
[18] G. Beck,et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.
[19] N. Powe,et al. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. , 2009, Journal of the American Society of Nephrology : JASN.
[20] G. Remuzzi,et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. , 2011, Journal of the American Society of Nephrology : JASN.
[21] Keith C. Norris,et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.
[22] Olivier Moranne,et al. Timing of onset of CKD-related metabolic complications. , 2009, Journal of the American Society of Nephrology : JASN.
[23] B. Eriksen,et al. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. , 2006, Kidney international.
[24] M. Donohue,et al. Pirfenidone for diabetic nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.
[25] Teven,et al. EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .
[26] Ann M. Johnson,et al. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] H. Taskapan,et al. Improvement in eGFR in patients with chronic kidney disease attending a nephrology clinic , 2008, International Urology and Nephrology.
[28] B. Kestenbaum,et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[29] G. Remuzzi,et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. , 1999, Journal of the American Society of Nephrology : JASN.
[30] K. Kalantar-Zadeh,et al. Association of disorders in mineral metabolism with progression of chronic kidney disease. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[31] G. Remuzzi,et al. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. , 2001, Journal of the American Society of Nephrology : JASN.
[32] A. Zeringue,et al. Rate of kidney function decline associates with mortality. , 2010, Journal of the American Society of Nephrology : JASN.
[33] M. Raftery,et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. , 2009, Journal of the American Society of Nephrology : JASN.
[34] P. Houillier,et al. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. , 2005, Journal of the American Society of Nephrology : JASN.
[35] T. Sakurai,et al. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. , 2010, The Journal of clinical investigation.
[36] C. Zoccali,et al. Vitamin D levels and patient outcome in chronic kidney disease. , 2009, Kidney international.
[37] P. Houillier,et al. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[38] G. Remuzzi,et al. Role of remission clinics in the longitudinal treatment of CKD. , 2008, Journal of the American Society of Nephrology : JASN.
[39] G. Beck,et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. , 1994, The New England journal of medicine.
[40] E. Ritz,et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. , 2003, Journal of the American Society of Nephrology : JASN.
[41] James Glockner,et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. , 2010, Journal of the American Society of Nephrology : JASN.
[42] D. Bates,et al. Diabetes, hemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.